WO2004059293A3 - Markers for differential diagnosis and methods of use thereof - Google Patents
Markers for differential diagnosis and methods of use thereof Download PDFInfo
- Publication number
- WO2004059293A3 WO2004059293A3 PCT/US2003/041453 US0341453W WO2004059293A3 WO 2004059293 A3 WO2004059293 A3 WO 2004059293A3 US 0341453 W US0341453 W US 0341453W WO 2004059293 A3 WO2004059293 A3 WO 2004059293A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- differential diagnosis
- markers
- diseases
- compositions
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9123—Phosphotransferases in general with a nitrogenous group as acceptor (2.7.3), e.g. histidine kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003302340A AU2003302340B8 (en) | 2002-12-24 | 2003-12-23 | Markers for differential diagnosis and methods of use thereof |
EP03810896A EP1587955A4 (en) | 2002-12-24 | 2003-12-23 | Markers for differential diagnosis and methods of use thereof |
CA002511501A CA2511501A1 (en) | 2002-12-24 | 2003-12-23 | Markers for differential diagnosis and methods of use thereof |
JP2005510072A JP2006526140A (en) | 2002-12-24 | 2003-12-23 | Marker for differential diagnosis and method of using the same |
IL169348A IL169348A0 (en) | 2002-12-24 | 2005-06-23 | Markers for differential diagnosis and methods of use thereof |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43630102P | 2002-12-24 | 2002-12-24 | |
US60/436,301 | 2002-12-24 | ||
US10/330,696 | 2002-12-27 | ||
US10/330,696 US7713705B2 (en) | 2002-12-24 | 2002-12-27 | Markers for differential diagnosis and methods of use thereof |
US10/371,149 | 2003-02-20 | ||
US10/371,149 US20030199000A1 (en) | 2001-08-20 | 2003-02-20 | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US10/603,891 | 2003-06-24 | ||
US10/603,891 US20040253637A1 (en) | 2001-04-13 | 2003-06-24 | Markers for differential diagnosis and methods of use thereof |
US10/673,077 US20040209307A1 (en) | 2001-08-20 | 2003-09-26 | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US10/673,077 | 2003-09-26 | ||
US10/714,078 US20040219509A1 (en) | 2001-08-20 | 2003-11-14 | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US10/714,078 | 2003-11-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004059293A2 WO2004059293A2 (en) | 2004-07-15 |
WO2004059293A3 true WO2004059293A3 (en) | 2005-03-31 |
Family
ID=32686403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/041453 WO2004059293A2 (en) | 2002-12-24 | 2003-12-23 | Markers for differential diagnosis and methods of use thereof |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1587955A4 (en) |
JP (1) | JP2006526140A (en) |
AU (1) | AU2003302340B8 (en) |
CA (1) | CA2511501A1 (en) |
WO (1) | WO2004059293A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
US8221995B2 (en) | 2007-03-23 | 2012-07-17 | Seok-Won Lee | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
US8450069B2 (en) | 2009-06-08 | 2013-05-28 | Singulex, Inc. | Highly sensitive biomarker panels |
US9494598B2 (en) | 2006-04-04 | 2016-11-15 | Singulex, Inc. | Highly sensitive system and method for analysis of troponin |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
MXPA03004105A (en) | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Making a prognosis in cases of cardiac disease using a combination of markers. |
BR0316232A (en) | 2002-11-12 | 2005-10-04 | Becton Dickinson Co | Methods for determining sepsis status, predicting the onset of sepsis, and diagnosing systemic inflammatory response syndrome in an individual |
BR0316197A (en) | 2002-11-12 | 2005-09-27 | Becton Dickinson Co | Kit, biomarker profile and method of isolating a host response biomarker |
EP1519194A1 (en) | 2003-09-24 | 2005-03-30 | Roche Diagnostics GmbH | Use of gfap for identification of intracerebral hemorrhage |
US20050196817A1 (en) | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
US8492107B2 (en) | 2004-04-15 | 2013-07-23 | University Of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
SI1747015T1 (en) * | 2004-04-26 | 2012-11-30 | Janssen Biotech Inc | Solution phase biopanning method using engineered decoy proteins |
US7501256B2 (en) | 2004-07-23 | 2009-03-10 | Aspenbio Pharma, Inc. | Methods and devices for diagnosis of appendicitis |
US7659087B2 (en) | 2004-07-23 | 2010-02-09 | Aspenbio Pharma, Inc. | Methods and devices for diagnosis of appendicitis |
DE102004041659A1 (en) * | 2004-08-27 | 2006-03-02 | Institut Virion/Serion Gmbh | Test device for the in vitro diagnosis of multi-analyte tests and their use |
ITFI20040243A1 (en) * | 2004-11-25 | 2005-02-25 | Paola Romagnani | DIAGNOSTIC METHOD FOR REJECTION OF TRANSPLANTED ORGAN |
EP1859283A1 (en) * | 2005-02-17 | 2007-11-28 | F. Hoffmann-Roche AG | Use of nt-proanp/nt-probnp ratio for diagnosing cardiac dysfunctions |
BRPI0609302A2 (en) | 2005-04-15 | 2011-10-11 | Becton Dickinson Co | methods for predicting the development of sepsis and for diagnosing sepsis in an individual to be tested, microarray, kit for predicting the development of sepsis in an individual to be tested, computer program product, computer, computer system for determining if an individual is likely to develop sepsis, digital signal embedded in a carrier wave, and, graphical user interface to determine if an individual is likely to develop sepsis |
US20070269836A1 (en) * | 2005-06-09 | 2007-11-22 | Mcpherson Paul H | Methods and compositions for the diagnosis of venous thromboembolic disease |
US20070099239A1 (en) * | 2005-06-24 | 2007-05-03 | Raymond Tabibiazar | Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease |
WO2007005426A2 (en) * | 2005-06-29 | 2007-01-11 | Rules-Based Medicine, Inc. | Methods and kits for the diagnosis of acute coronary syndrome |
CA2614737A1 (en) * | 2005-07-08 | 2007-01-18 | Philadelphia Health & Education Corporation D/B/A Drexel University Coll Ege Of Medicine | Methods for monitoring neuroinflammatory destruction of neurons and for treating diseases having an inflammatory component related to phospholipase a2 |
US20090226898A1 (en) * | 2005-07-14 | 2009-09-10 | Inverness Medical Switzerland Gmbh | Mitochondrial markers of ischemia |
DE102005034174A1 (en) * | 2005-07-21 | 2007-02-08 | B.R.A.H.M.S Ag | CSF in vitro diagnostic procedure for dementia and neuroinflammatory diseases |
DE102005036094A1 (en) * | 2005-08-01 | 2007-02-08 | B.R.A.H.M.S Ag | In vitro method for the diagnosis of neurodegenerative diseases |
JP2007082433A (en) * | 2005-09-20 | 2007-04-05 | Niigata Univ | Malignant brain tumor marker gene and use of the same |
WO2007041645A2 (en) * | 2005-10-03 | 2007-04-12 | Scios Inc. | Oxidized human bnp |
AU2006333077A1 (en) * | 2005-12-15 | 2007-07-12 | Becton, Dickinson And Company | Diagnosis of sepsis |
EP1845379A1 (en) | 2006-04-13 | 2007-10-17 | F. Hoffmann-La Roche AG | Means and methods for the differentiation of cardiac and pulmonary causes of shortness of breath |
KR20090034811A (en) | 2006-05-09 | 2009-04-08 | 무스크 파운데이션 포 리서치 디벨롭먼트 | Detecting diastolic heart failure by protease and protease inhibitor plasma profiling |
DE102006023175A1 (en) * | 2006-05-17 | 2007-11-22 | B.R.A.H.M.S Aktiengesellschaft | In vitro diagnostic and early diagnosis of neurodegenerative diseases |
DE102006027818A1 (en) * | 2006-06-16 | 2007-12-20 | B.R.A.H.M.S. Aktiengesellschaft | In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative diseases |
DE102006034142A1 (en) * | 2006-07-24 | 2008-01-31 | B.R.A.H.M.S. Aktiengesellschaft | Method for controlling the therapy of heart failure patients by the in vitro determination of threshold levels of vasoactive peptides |
EP1882947A1 (en) * | 2006-07-28 | 2008-01-30 | F. Hoffmann-La Roche AG | Means and methods for the differentation of cardiac and pulmonary causes of acute shortness of breath |
BRPI0715126B8 (en) * | 2006-08-04 | 2021-07-27 | Medizinische Hochschule Hannover | methods for risk assessment of cardiac interventions and gdf-15-based uses |
CA2660286A1 (en) * | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
EP1909206A1 (en) * | 2006-09-11 | 2008-04-09 | Roche Diagnostics GmbH | Improvement of measuring range of a chromatographic rapid test |
ES2334155T3 (en) * | 2006-09-15 | 2010-03-05 | F. Hoffmann-La Roche Ag | BIOCHEMICAL MARKERS FOR ACUTE PULMONARY EMBOLISM. |
US8449864B2 (en) | 2006-10-20 | 2013-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Neurotensin as a marker and therapeutic target for sepsis |
DE102006053442A1 (en) * | 2006-11-12 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnosis and risk stratification of infections and chronic diseases of the respiratory and lungs by means of proVasopressin, in particular copeptin or neurophysin II |
US8524462B2 (en) | 2006-11-14 | 2013-09-03 | Alere San Diego, Inc. | Methods and compositions for diagnosis and prognosis of renal artery stenosis |
WO2008060607A2 (en) | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for monitoring and risk prediction in cardiorenal syndrome |
SE532103C2 (en) | 2006-12-12 | 2009-10-27 | Knut Johansen | Method for determining the health status of analytes in liquid samples |
DE102007022367A1 (en) * | 2007-05-07 | 2008-11-20 | B.R.A.H.M.S Ag | Method for the determination of amino-terminal pro-ANP in overweight patients |
US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
EP2019318A1 (en) * | 2007-07-27 | 2009-01-28 | Erasmus University Medical Center Rotterdam | Protein markers for cardiovascular events |
EP2020603A1 (en) * | 2007-08-03 | 2009-02-04 | BRAHMS Aktiengesellschaft | Method for risk stratification in stable coronary artery disease |
JP5059943B2 (en) | 2007-08-03 | 2012-10-31 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Use of procalcitonin (PCT) in risk stratification and in vitro methods for performing prognosis of patients with primary non-infectious diseases |
US8431367B2 (en) | 2007-09-14 | 2013-04-30 | Predictive Biosciences Corporation | Detection of nucleic acids and proteins |
US20090075266A1 (en) * | 2007-09-14 | 2009-03-19 | Predictive Biosciences Corporation | Multiple analyte diagnostic readout |
EP2031397A1 (en) * | 2007-08-30 | 2009-03-04 | F. Hoffmann-La Roche AG | Surfactant proteins B and D in differentiating the causes of shortness of breath |
US8852893B2 (en) | 2007-09-14 | 2014-10-07 | Physicians Choice Laboratory Services, Llc | Detection of nucleic acids and proteins |
US7955822B2 (en) | 2007-09-14 | 2011-06-07 | Predictive Biosciences Corp. | Detection of nucleic acids and proteins |
WO2009083020A1 (en) | 2007-12-28 | 2009-07-09 | F. Hoffmann-La Roche Ag | Assessment of physiological conditions |
CA2717763A1 (en) * | 2008-03-04 | 2009-09-11 | John Bilello | Diagnosing and monitoring depression disorders based on multiple biomarker panels |
JP5574990B2 (en) * | 2008-03-10 | 2014-08-20 | リニーゲン、インコーポレイテッド | COPD biomarker signature |
CN102016907A (en) * | 2008-03-12 | 2011-04-13 | 瑞吉诊断公司 | Inflammatory biomarkers for monitoring depression disorders |
US7776522B2 (en) | 2008-04-24 | 2010-08-17 | Becton, Dickinson And Company | Methods for diagnosing oncogenic human papillomavirus (HPV) |
JP2011528115A (en) * | 2008-07-14 | 2011-11-10 | エフ.ホフマン−ラ ロシュ アーゲー | Multi-marker panel for diagnosis, monitoring and treatment selection of patients with heart failure |
WO2010017972A1 (en) * | 2008-08-13 | 2010-02-18 | Roche Diagnostics Gmbh | D-dimer, troponin, nt-probnp for pulmonary embolism |
EP2166358A1 (en) * | 2008-09-17 | 2010-03-24 | Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron | Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof |
JP5219048B2 (en) * | 2008-09-17 | 2013-06-26 | 独立行政法人農業・食品産業技術総合研究機構 | Method for evaluating animal stress using anti-porcine interleukin-18 antibody |
CN102257386B (en) * | 2008-10-24 | 2014-12-31 | B.R.A.H.M.S有限公司 | Prognosis and risk assessment in stroke patients by determining the level of marker peptides |
CN102301234B (en) * | 2008-11-18 | 2015-06-17 | 里奇诊断学股份有限公司 | Metabolic Syndrome And HPA Axis Biomarkers For Major Depressive Disorder |
CA2754961C (en) | 2009-03-11 | 2018-04-10 | Promedior, Inc. | Treatment and diagnostic methods for hypersensitive disorders |
AU2010224172B2 (en) | 2009-03-11 | 2016-01-21 | Promedior, Inc. | Treatment methods for autoimmune disorders |
MX2011011958A (en) | 2009-05-11 | 2012-02-13 | Berg Biosystems Llc | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers. |
UA110323C2 (en) | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
US9752191B2 (en) | 2009-07-09 | 2017-09-05 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
WO2011023813A1 (en) | 2009-08-28 | 2011-03-03 | Brahms Gmbh | Procalcitonin for the prognosis of adverse events |
JP5909447B2 (en) | 2009-09-14 | 2016-04-26 | バンヤン・バイオマーカーズ・インコーポレーテッド | MicroRNAs, autoantibodies and protein markers for neuronal damage diagnosis |
CA2784889C (en) | 2009-12-20 | 2018-06-19 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
CN102791885B (en) * | 2010-02-05 | 2015-09-09 | 阿斯图特医药公司 | For the method and composition of the diagnosis and prognostic of injury of the kidney and renal failure |
WO2011110565A1 (en) * | 2010-03-08 | 2011-09-15 | B.R.A.H.M.S Gmbh | Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints |
WO2011119637A1 (en) | 2010-03-22 | 2011-09-29 | Stemina Biomarker Discovery, Inc. | Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics |
JP6021187B2 (en) | 2010-04-29 | 2016-11-09 | ウィスコンシン・アルムニ・リサーチ・ファウンデーションWisconsin Alumni Research Foundation | Metabolic biomarkers of autism |
CA2798149A1 (en) | 2010-05-06 | 2011-11-10 | Singulex, Inc | Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis |
WO2012013758A2 (en) * | 2010-07-28 | 2012-02-02 | Abbott Gmbh & Co. Kg | Method for detection of ischemic strokes |
US20130338194A1 (en) * | 2010-11-11 | 2013-12-19 | Medical University Of South Carolina | Predicting Atrial Fibrillation Recurrence by Protease and Protease Inhibitor Profiling |
EP2492691A1 (en) | 2011-02-22 | 2012-08-29 | Institut de Recerca Hospital Universitari Vall d'Hebron | Method of predicting the evolution of a patient suffering of a neurovascular disease |
CN103403555B (en) | 2011-03-11 | 2015-06-24 | 霍夫曼-拉罗奇有限公司 | ASC as marker for chronic obstructive pulmonary disease (COPD) |
ES2762451T3 (en) | 2011-04-04 | 2020-05-25 | Berg Llc | Treatment of tumors of the central nervous system with coenzyme Q10 |
KR101894417B1 (en) | 2011-05-09 | 2018-09-03 | 세키스이 메디칼 가부시키가이샤 | Method for immunologically measuring soluble lr11 |
RU2469332C1 (en) * | 2011-10-12 | 2012-12-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации | Differential diagnostic technique for bronchial asthma |
SG2014014559A (en) | 2011-10-17 | 2014-08-28 | Hoffmann La Roche | Troponin and bnp based diagnosis of risk patients and cause of stroke |
ES2656082T3 (en) * | 2011-12-01 | 2018-02-23 | F. Hoffmann-La Roche Ag | NT-proANP and NT-proBNP for the diagnosis of stroke |
WO2013086359A1 (en) | 2011-12-08 | 2013-06-13 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
EP2597465A1 (en) * | 2012-06-26 | 2013-05-29 | Roche Diagniostics GmbH | TnT and H-FABP for diagnosis of cardiac damage in infection |
JP6366594B2 (en) | 2012-11-09 | 2018-08-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Method for providing data for diagnosing paroxysmal atrial fibrillation based on TnT |
US9414752B2 (en) | 2012-11-09 | 2016-08-16 | Elwha Llc | Embolism deflector |
PL2946211T3 (en) | 2013-01-17 | 2018-08-31 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
WO2014120731A1 (en) * | 2013-02-01 | 2014-08-07 | West Virginia University | A biomarker algorithm for determining the time of stroke symptom onset and method |
KR101494882B1 (en) | 2013-02-21 | 2015-02-25 | 한국과학기술연구원 | A composition for diagnosing acute myocardial infarction, a kit for diagnosing acute myocardial infarction comprising the composition, and a method for diagnosing acute myocardial infarction |
CN113797343A (en) | 2013-04-08 | 2021-12-17 | 博格有限责任公司 | Treatment of cancer using coenzyme Q10 combination therapy |
GB201309928D0 (en) * | 2013-06-04 | 2013-07-17 | Randox Lab Ltd | Method |
WO2015009907A1 (en) | 2013-07-17 | 2015-01-22 | The Johns Hopkins University | A multi-protein biomarker assay for brain injury detection and outcome |
JP2016532115A (en) * | 2013-08-30 | 2016-10-13 | メタノミクス ゲーエムベーハー | Means and methods for diagnosing heart failure in a subject |
WO2015035094A1 (en) | 2013-09-04 | 2015-03-12 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
FR3010187A1 (en) * | 2013-09-05 | 2015-03-06 | Ct Hospitalier Universitaire Rouen | USE OF UROTENSIN II AND / OR URP AS MARKERS FOR THE DIAGNOSIS OF POST HSA VASOSPASM |
WO2015179773A1 (en) | 2014-05-22 | 2015-11-26 | The Scripps Research Institute | Tissue molecular signatures of kidney transplant rejections |
CN105556308B (en) | 2013-09-20 | 2018-05-29 | 阿斯图特医药公司 | For the method and composition of the differentiation of the diagnosis and prognosis and the abdominal pain cause of disease of appendicitis |
JP2017500547A (en) * | 2013-11-15 | 2017-01-05 | オタゴ イノベーション リミテッド | Biomarkers for heart failure |
US9176113B1 (en) | 2014-04-11 | 2015-11-03 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
US20150294081A1 (en) | 2014-04-11 | 2015-10-15 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
EP3146076A4 (en) | 2014-05-22 | 2018-05-09 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
US11104951B2 (en) | 2014-05-22 | 2021-08-31 | The Scripps Research Institute | Molecular signatures for distinguishing liver transplant rejections or injuries |
AU2015263998A1 (en) | 2014-05-22 | 2016-12-08 | Northwestern University | Gene expression profiles associated with sub-clinical kidney transplant rejection |
EP3502271A3 (en) * | 2014-10-22 | 2019-08-14 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Blood biomarkers for appendicitis and diagnostics methods using biomarkers |
US10525020B2 (en) | 2015-02-11 | 2020-01-07 | Laboratory Corporation Of America Holdings | Metabolic markers of attention deficit hyperactivity disorder |
US10690681B2 (en) | 2015-03-06 | 2020-06-23 | Washington University | Methods to detect myocardial injury and uses thereof |
WO2017067821A1 (en) * | 2015-10-22 | 2017-04-27 | Universite Pierre Et Marie Curie (Paris 6) | A method for determining presence or risk of hemostasis disorder |
KR101801092B1 (en) | 2016-01-28 | 2017-11-28 | 순천향대학교 산학협력단 | Composition for Idiopathic pulmonary fibrosis prognosis and method of providing the information for the same |
US11243217B2 (en) | 2016-06-06 | 2022-02-08 | Astute Medical, Inc. | Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 |
CN108728525B (en) * | 2017-04-19 | 2021-06-22 | 香港中文大学 | Circulating microRNA biomarker for subarachnoid hemorrhage and application thereof |
WO2018229051A1 (en) * | 2017-06-13 | 2018-12-20 | Roche Diagnostics Gmbh | Fatty acid binding protein 3 for the assessment of atrial fibrillation (af) |
WO2019018545A1 (en) | 2017-07-18 | 2019-01-24 | The Research Foundation For The State University Of New York | Biomarkers for intracranial aneurysm |
CN109975548B (en) * | 2018-03-08 | 2020-08-07 | 中山大学 | Application of IgG4 detection reagent in preparation of colorectal cancer diagnostic agent |
JP7185947B2 (en) * | 2018-03-30 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Severity determination method and prognosis prediction method for neonatal hypoxic-ischemic encephalopathy |
EP3553520A1 (en) * | 2018-04-12 | 2019-10-16 | Koninklijke Philips N.V. | Methods, uses and kits for monitoring or predicting response to periodontal disease treatment |
EP3553518A1 (en) * | 2018-04-12 | 2019-10-16 | Koninklijke Philips N.V. | Periodontitis diagnostic methods, uses and kits |
EP3553525A1 (en) * | 2018-04-12 | 2019-10-16 | Koninklijke Philips N.V. | Diagnostics of mild or advanced periodontitis |
EP3553524A1 (en) * | 2018-04-12 | 2019-10-16 | Koninklijke Philips N.V. | Periodontitis diagnostic methods, uses and kits |
JP7398226B2 (en) | 2019-09-03 | 2023-12-14 | 浜松ホトニクス株式会社 | Methods for assessing the risk of developing colorectal cancer |
WO2021199792A1 (en) * | 2020-04-02 | 2021-10-07 | 国立大学法人大阪大学 | Formulation for preventing or treating pneumonia |
CN114015759B (en) * | 2020-07-24 | 2022-08-19 | 首都医科大学附属北京天坛医院 | Biomarker for prognosis or recurrence early warning evaluation of acute ischemic stroke and application thereof |
CN113252910B (en) * | 2021-06-29 | 2022-05-17 | 中国人民解放军军事科学院军事医学研究院 | Application of TIMP3 in anxiety and depression diagnosis |
CN115287346A (en) * | 2022-05-26 | 2022-11-04 | 中山大学深圳研究院 | Acute myocardial infarction early detection marker and detection kit |
CN116059328A (en) * | 2022-09-14 | 2023-05-05 | 深圳先进技术研究院 | Application of TIMP3 recombinant protein in preparation of preparation for inhibiting hypertensive renal clear cell carcinoma |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5599668A (en) * | 1994-09-22 | 1997-02-04 | Abbott Laboratories | Light scattering optical waveguide method for detecting specific binding events |
US6214560B1 (en) * | 1996-04-25 | 2001-04-10 | Genicon Sciences Corporation | Analyte assay using particulate labels |
WO2003016910A1 (en) * | 2001-08-20 | 2003-02-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20030153014A1 (en) * | 1999-10-08 | 2003-08-14 | Li Shen | Compositions and methods for detecting protein modification and enzymatic activity |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604105B1 (en) * | 1990-10-12 | 1999-08-24 | Spectral Diagnostics Inc | Method and device for diagnosingand distinguishing chest pain in early onset thereof |
CA2263063C (en) * | 1999-02-26 | 2004-08-10 | Skye Pharmatech Incorporated | Method for diagnosing and distinguishing stroke and diagnostic devices for use therein |
AUPR005600A0 (en) * | 2000-09-12 | 2000-10-05 | University Of Sydney, The | Diagnostic assay |
US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
DE60235416D1 (en) * | 2001-05-04 | 2010-04-01 | Biosite Inc | Diagnostic markers of acute coronary syndromes and their uses |
-
2003
- 2003-12-23 JP JP2005510072A patent/JP2006526140A/en active Pending
- 2003-12-23 AU AU2003302340A patent/AU2003302340B8/en not_active Expired
- 2003-12-23 CA CA002511501A patent/CA2511501A1/en not_active Abandoned
- 2003-12-23 WO PCT/US2003/041453 patent/WO2004059293A2/en active Application Filing
- 2003-12-23 EP EP03810896A patent/EP1587955A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5599668A (en) * | 1994-09-22 | 1997-02-04 | Abbott Laboratories | Light scattering optical waveguide method for detecting specific binding events |
US6214560B1 (en) * | 1996-04-25 | 2001-04-10 | Genicon Sciences Corporation | Analyte assay using particulate labels |
US20030153014A1 (en) * | 1999-10-08 | 2003-08-14 | Li Shen | Compositions and methods for detecting protein modification and enzymatic activity |
WO2003016910A1 (en) * | 2001-08-20 | 2003-02-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
Non-Patent Citations (1)
Title |
---|
See also references of EP1587955A4 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
US8343728B2 (en) | 2006-04-04 | 2013-01-01 | Singulex, Inc. | Highly sensitive system and method for analysis of troponin |
US8535895B2 (en) | 2006-04-04 | 2013-09-17 | Singulex, Inc. | Highly sensitive system and method for analysis of troponin |
US9182405B2 (en) | 2006-04-04 | 2015-11-10 | Singulex, Inc. | Highly sensitive system and method for analysis of troponin |
US9494598B2 (en) | 2006-04-04 | 2016-11-15 | Singulex, Inc. | Highly sensitive system and method for analysis of troponin |
US8221995B2 (en) | 2007-03-23 | 2012-07-17 | Seok-Won Lee | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
US8450069B2 (en) | 2009-06-08 | 2013-05-28 | Singulex, Inc. | Highly sensitive biomarker panels |
Also Published As
Publication number | Publication date |
---|---|
JP2006526140A (en) | 2006-11-16 |
WO2004059293A2 (en) | 2004-07-15 |
EP1587955A2 (en) | 2005-10-26 |
AU2003302340B2 (en) | 2008-08-21 |
CA2511501A1 (en) | 2004-07-15 |
EP1587955A4 (en) | 2007-03-14 |
AU2003302340B8 (en) | 2008-09-11 |
AU2003302340A1 (en) | 2004-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004059293A3 (en) | Markers for differential diagnosis and methods of use thereof | |
WO2002042775A3 (en) | Clinically intelligent diagnostic devices and methods | |
WO2005027733A3 (en) | Biological markers for diagnosing multiple sclerosis | |
WO2005114190A3 (en) | Methods of identifying biomarkers | |
WO2003000853A3 (en) | Protein aggregation assays and uses thereof | |
WO2006071247A3 (en) | Diagnostic assays including multiplexed lateral flow immunoassays with quantum dots | |
WO2002089657A3 (en) | Diagnostic markers of acute coronary syndromes and methods of use thereof | |
MXPA04000062A (en) | Homocysteinylated transthyretin. | |
WO2005058961A3 (en) | Antibodies specific for human galanin, and uses thereof | |
WO2004048598A3 (en) | Molecular nephrotoxicology modeling | |
WO2003023573A3 (en) | Patient classification | |
WO2002095000A8 (en) | Molecular toxicology modeling | |
BRPI0114343B8 (en) | method for detecting immunoglobulin ige and for in vitro diagnosis of allergies, as well as microarray chip and kit comprising it | |
WO2004063753A3 (en) | A serum marker for measuring liver fibrosis | |
WO2006128042A3 (en) | Methods of identifying mutations in nucleic acid | |
WO2009126969A3 (en) | Biomarkers for endometrial disease | |
WO2004007743A3 (en) | Use of cpg nucleic acids in prion-disease | |
WO2007132120A3 (en) | Procedure and methods for detecting alzheimer's disease | |
WO2002086448A3 (en) | Detection of microsatellite instability and its use in diagnosis of tumors | |
FR2924118B1 (en) | INHIBITOR FRAGMENTS OF THE NEF PROTEIN OF HIV. | |
WO2006099543A3 (en) | Methods for assessing antibody-mediated cytotoxicity | |
BR0014150A (en) | Diagnostics and therapeutics for osteoporosis | |
WO2007061988A3 (en) | Methods for determining notch signaling and uses thereof | |
WO2006002930A3 (en) | FcϜRIIa POLYMORPHISM AND ITS USE IN DIAGNOSIS | |
WO2004063334A8 (en) | Molecular cardiotoxicology modeling |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2511501 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 169348 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005510072 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3018/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003302340 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003810896 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A98399 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003810896 Country of ref document: EP |